Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-68179280 in Healthy Participants
NCT04844463Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-68179280 in inflammatory bowel disease (IBD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Treatment-emergent Adverse Events up to 35 days, Number of Participants with Treatment-emergent Serious Adverse Events up to 35 days and 4 more. Started May 2021; status: completed.
02
Drugs
JNJ-68179280
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT04844463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844463.